drugset / Trial / NCT05632861
HuHuangLianzonggan Capsule in Subjects With Nonalcoholic Steatohepatitis: a Phase 2 tRial(HHL-HEPAR)
RandomizedParallel-groupQuadruple-blindTreatment
Summary
This study will evaluate the efficacy and safety and the best effective dose of HuHuangLianzonggan capsule in subjects with nonalcoholic steatohepatitis.
Timeline
- Start
- 2023-02-21
- Primary completion
- 2024-12-31
- Completion
- 2024-12-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | HuHuangLianzonggan capsule | Unknown | 480 mg | Oral |